MDT-AP-0121
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 80.64
- os_event
- false
- age_years
- 12
- sex
- M
- new_clusters
- C6
- umap1_2d
- 2.899234423
- umap2_2d
- 6.569654332
- umap1_3d
- 1.850804657
- umap2_3d
- 0.229136936
- umap3_3d
- -3.936136102
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.310
- G2M_CHECKPOINT+0.160
- COMPLEMENT+0.110
- MITOTIC_SPINDLE+0.110
- SPERMATOGENESIS+0.100
- PANCREAS_BETA_CELLS+0.090
- BILE_ACID_METABOLISM+0.070
- KRAS_SIGNALING_DN+0.040
- PROTEIN_SECRETION+0.040
- COAGULATION+0.030
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- CHOLESTEROL_HOMEOSTASIS-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- MTORC1_SIGNALING-0.350
- TNFA_SIGNALING_VIA_NFKB-0.350
- P53_PATHWAY-0.300
- MYC_TARGETS_V1-0.290
- NOTCH_SIGNALING-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.280
- ESTROGEN_RESPONSE_EARLY-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2932842 | — | — | 0.770 |
| 2 | SRR12202443 | — | — | 0.761 |
| 3 | SRR1797261 | — | cohortSC | 0.761 |
| 4 | ERR4976603 | — | E | 0.760 |
| 5 | 8e33d29d-23c9-48f4-89a2-d0a9b17d0081 | — | — | 0.751 |
| 6 | ERR4976605 | — | D | 0.748 |
| 7 | SRR627429 | GTEX | — | 0.747 |
| 8 | SRR627462 | GTEX | — | 0.746 |
| 9 | SRR934779 | — | — | 0.743 |
| 10 | SRR12202440 | — | — | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.040 | Remibrutinib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.010 | Idelalisib | — uncovered |